Understanding CAR T-cell therapy (November 2020)
Presented by Dr Michael Dickinson, Peter MacCallum Cancer Centre & Royal Melbourne Hospital
Hosted by Donna Gairns, National Nurse Manager, Lymphoma Australia
Dr Michael Dickinson, is a Consultant Haematologist at Peter MacCallum Cancer Centre & Royal Melbourne Hospital and disease group lead for aggressive lymphoma. Dr Dickinson has a special interest in lymphoma and is leading the development of new targeted, non-chemotherapy drugs as the principal investigator of many trials of new treatments. He is
the local investigator on a range of CAR T-cell therapy trials. Dr Dickinson has been instrumental in helping in the recent approval of publicly funded CAR T-cell therapy to Australian patients.
CAR T-cell therapy is a relatively new therapy that has gained a lot of attention in the treatment of lymphoma/CLL in recent years. Dr Dickinson provides a thorough presentation that is relevant to Australian lymphoma/CLL patients in November 2020 in an exciting area that is changing rapidly.
The presentation includes:
- What is CAR T-cell therapy?
- How does CAR T-cell therapy work?
- What is the process?
- Side effects of CAR T-cell therapy
- What subtypes are currently being treated in Australia & worldwide
- CAR T-cell therapy funding in Australia
- Clinical trials available in Australia and around the world
For more information see the Lymphoma Australia website:
Chimeric antigen receptor (CAR) T-cell therapy:
www.lymphoma.org.au/about-lym...
Chimeric antigen receptor (CAR) T-cell therapy fact sheet:
www.lymphoma.org.au/wp-conten...
Contact the Lymphoma Australia Nurse Support line or email us:
Phone 1800 953 081
Email: nurse@lymphoma.org.au